Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series

Marcella Pellegrino; Luisa D’Oria; Carmen De Luca; Giacomina Chiaradia; Angelo Licameli; Caterina Neri; Marta Nucci; Daniela Visconti; Alessandro Caruso; Marco De Santis

doi:10.2174/1574886312666171030125804

Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series

Marcella Pellegrino, Luisa D’Oria, Carmen De Luca, Giacomina Chiaradia, Angelo Licameli, Caterina Neri, Marta Nucci, Daniela Visconti, Alessandro Caruso, Marco De Santis

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Review article

Abstract

Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

Original language	English
Pages (from-to)	3-11
Number of pages	9
Journal	Current Drug Safety
Volume	13
Issue number	1
DOIs	https://doi.org/10.2174/1574886312666171030125804
Publication status	Published - Mar 1 2018

Keywords

Congenital anomalies
Drugs
Glaucoma
Pregnancy
Prenatal diagnosis
Teratology Information Service (TIS)

ASJC Scopus subject areas

Toxicology
Pharmacology
Pharmacology (medical)

Access to Document

10.2174/1574886312666171030125804

Fingerprint Dive into the research topics of 'Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series'. Together they form a unique fingerprint.

Cite this

Pellegrino, M., D’Oria, L., De Luca, C., Chiaradia, G., Licameli, A., Neri, C., Nucci, M., Visconti, D., Caruso, A., & De Santis, M. (2018). Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series. Current Drug Safety, 13(1), 3-11. https://doi.org/10.2174/1574886312666171030125804

Glaucoma drug therapy in pregnancy : Literature review and teratology information service (TIS) case series. / Pellegrino, Marcella; D’Oria, Luisa; De Luca, Carmen; Chiaradia, Giacomina; Licameli, Angelo; Neri, Caterina; Nucci, Marta; Visconti, Daniela; Caruso, Alessandro; De Santis, Marco.

In: Current Drug Safety, Vol. 13, No. 1, 01.03.2018, p. 3-11.

Research output: Contribution to journal › Review article

@article{2b70befeb53f4ece9286c6c383ef663f,

title = "Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series",

abstract = "Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.",

keywords = "Congenital anomalies, Drugs, Glaucoma, Pregnancy, Prenatal diagnosis, Teratology Information Service (TIS)",

author = "Marcella Pellegrino and Luisa D{\textquoteright}Oria and {De Luca}, Carmen and Giacomina Chiaradia and Angelo Licameli and Caterina Neri and Marta Nucci and Daniela Visconti and Alessandro Caruso and {De Santis}, Marco",

year = "2018",

month = mar,

day = "1",

doi = "10.2174/1574886312666171030125804",

language = "English",

volume = "13",

pages = "3--11",

journal = "Current Drug Safety",

issn = "1574-8863",

publisher = "Bentham Science Publishers B.V.",

number = "1",

}

TY - JOUR

T1 - Glaucoma drug therapy in pregnancy

T2 - Literature review and teratology information service (TIS) case series

AU - Pellegrino, Marcella

AU - D’Oria, Luisa

AU - De Luca, Carmen

AU - Chiaradia, Giacomina

AU - Licameli, Angelo

AU - Neri, Caterina

AU - Nucci, Marta

AU - Visconti, Daniela

AU - Caruso, Alessandro

AU - De Santis, Marco

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

AB - Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

KW - Congenital anomalies

KW - Drugs

KW - Glaucoma

KW - Pregnancy

KW - Prenatal diagnosis

KW - Teratology Information Service (TIS)

UR - http://www.scopus.com/inward/record.url?scp=85045985080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045985080&partnerID=8YFLogxK

U2 - 10.2174/1574886312666171030125804

DO - 10.2174/1574886312666171030125804

M3 - Review article

C2 - 29086700

AN - SCOPUS:85045985080

VL - 13

SP - 3

EP - 11

JO - Current Drug Safety

JF - Current Drug Safety

SN - 1574-8863

IS - 1

ER -